Company Overview of Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc., a biopharmaceutical company, primarily engages in the discovery and development of a class of therapeutic drugs for the treatment of cancer and other pathological conditions. Its proprietary drug discovery and development program consists of therapeutics developed from amphibian ribonucleases. The company’s lead drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. Tamir Biotechnology also focuses on new drug application for unresectable malignant mesothelioma. In addition, it completed a Phase I clinical trial for the treatment of non-small cell lung cancer. The company was formerly known as Alfacell C...
12625 High Bluff Drive
San Diego, CA 92130
Founded in 1981
Key Executives for Tamir Biotechnology, Inc.
Chief Executive Officer, President, Secretary, and Director
Chief Financial Officer and Secretary
Chairman of the Thoracic Cancer Advisory Board
Special Advisor to Chief Executive Officer
Compensation as of Fiscal Year 2014.
Tamir Biotechnology, Inc. Key Developments
Tamir Biotechnology, Inc. Presents at The 7th Annual OneMedForum San Francisco 2014 Conference, Jan-13-2014
Dec 23 13
Tamir Biotechnology, Inc. Presents at The 7th Annual OneMedForum San Francisco 2014 Conference, Jan-13-2014 . Venue: Westin San Francisco Market Street, San Francisco, California, United States.
SEC Revokes Registration Of Registered Securities Of Tamir Biotechnology
May 22 13
An Administrative Law Judge has issued an Initial Decision as to Tamir Biotechnology, Inc. (Tamir), in Medis Technologies Ltd., Admin. Proc. File No. 3-15185. The Order Instituting Proceedings alleged that Tamir repeatedly failed to file required annual and quarterly reports while its securities were registered with the Securities and Exchange Commission (SEC). The Initial Decision finds these allegations to be true and revokes the registration of the registered securities of Tamir, pursuant to Section 12(j) of the Securities Exchange Act of 1934 (Exchange Act).
Tamir Biotechnology, Inc. Announces Auditor Changes
Mar 28 13
On March 25, 2013, following the recommendation of its Audit Committee, Tamir Biotechnology, Inc., dismissed CohnReznick LLP as the Company’s independent registered public accounting firm. On March 25, 2013, following the recommendation of its Audit Committee, the Company engaged Goldman Kurland and Mohidin, LLP, as its independent accountants to audit the Company's financial statements for its fiscal years ended July 31, 2011, 2012 and 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 25, 2014